Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing.

被引:98
|
作者
Wu, Jiang [2 ]
Xu, Fujie [1 ]
Lu, Li [2 ]
Lu, Min [2 ]
Miao, Liang [2 ]
Gao, Ting [2 ]
Ji, Wenyan [2 ]
Suo, Luodan [2 ]
Liu, Donglei [2 ]
Ma, Rui [2 ]
Yu, Rui [2 ]
Zhangzhu, Jiazi [2 ]
Liu, Weixiang [2 ]
Zeng, Yang [2 ]
Li, Xiaomei [2 ]
Zhang, Xuechun [2 ]
Pang, Xinghuo [2 ]
Deng, Ying [2 ]
机构
[1] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA
[2] Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 363卷 / 25期
关键词
GUILLAIN-BARRE-SYNDROME; INFLUENZA; VIRUS; CHINA;
D O I
10.1056/NEJMoa1006736
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: After the first monovalent 2009 pandemic influenza A (H1N1) vaccine became available in September 2009, Chinese officials conducted a mass vaccination program in Beijing. We evaluated the safety and effectiveness of the vaccine. Methods: During a 5-day period in September 2009, a total of 95,244 children and adults received the PANFLU.1 vaccine (Sinovac Biotech), a monovalent split-virion vaccine of 15 microg of hemagglutinin antigen without adjuvant. We assessed adverse events after immunization through an enhanced passive-surveillance system and through active surveillance, using diary cards and telephone interviews. Active surveillance for neurologic diseases was implemented in hospitals citywide. To assess vaccine effectiveness, we compared the rates of reported laboratory-confirmed cases of 2009 H1N1 virus infection in students who received the vaccine with the rates in those who did not receive the vaccine, starting 2 weeks after the mass vaccination. Results: As of December 31, 2009, adverse events were reported by 193 vaccine recipients. Through hospital-based active surveillance, 362 cases of incident neurologic diseases were identified within 10 weeks after the mass vaccination, including 27 cases of the Guillain-Barre syndrome. None of the neurologic conditions occurred among vaccine recipients. From 245 schools, 25,037 students participated in the mass vaccination and 244,091 did not. During the period from October 9 through November 15, 2009, the incidence of confirmed cases of 2009 H1N1 virus infection per 100,000 students was 35.9 (9 of 25,037) among vaccinated students and 281.4 (687 of 244,091) among unvaccinated students. Thus, the estimated vaccine effectiveness was 87.3% (95% confidence interval, 75.4 to 93.4). Conclusions: Among 95,244 children and adults in Beijing, the PANFLU.1 vaccine had a safety profile similar to those of seasonal influenza vaccines and appeared to be effective against confirmed H1N1 virus infection in school-age children. (Funded by the Beijing Municipal Health Bureau.) N Engl J Med 2010;363:2416-23.
引用
收藏
页码:2416 / 2423
页数:8
相关论文
共 50 条
  • [1] Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing
    Kelley, Nicholas S.
    Osterholm, Michael T.
    Belongia, Edward A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12): : 1181 - 1181
  • [2] Safety and Effectiveness of a 2009 H1N1 Vaccine in Chronic Kidney Disease Children
    Donmez, Osman
    Akaci, Okan
    Albayrak, Nurhan
    Altas, Ayse
    [J]. NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 341 - 344
  • [3] Safety and effectiveness of a 2009 H1N1 vaccine in chronic kidney disease children
    Donmez, O.
    Korkmaz, A.
    Akaci, O.
    Durmaz, O.
    Albayrak, N.
    Altas, A. B.
    [J]. PEDIATRIC NEPHROLOGY, 2011, 26 (09) : 1621 - 1621
  • [4] Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea
    Song, Joon Young
    Cheong, Hee Jin
    Heo, Jung Yeon
    Noh, Ji Yun
    Choi, Won Suk
    Park, Dae Won
    Lee, Jacob
    Jeong, Hye Won
    Kee, Sae Yoon
    Kim, Woo Joo
    [J]. VACCINE, 2011, 29 (07) : 1395 - 1398
  • [5] Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients
    Lertdumrongluk, Paungpaga
    Changsirikulchai, Siribha
    Limkunakul, Chutatip
    Prachukthum, Poonsuk
    Punpiput, Prapaipun
    Buppanharun, Rungtiva
    Chotpitayasunondh, Chuencheevit
    [J]. VACCINE, 2012, 30 (06) : 1108 - 1114
  • [6] Effectiveness and Safety of Pandemic Influenza A (H1N1) 2009 Vaccine in Healthcare Workers at a University Hospital in Japan
    Igari, Hidetoshi
    Watanabe, Akira
    Chiba, Hitoshi
    Shoji, Kyoko
    Segawa, Shunsuke
    Nakamura, Yasutaka
    Watanabe, Masaharu
    Suzuki, Kazuo
    Sato, Takeyuki
    [J]. JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2011, 64 (03) : 177 - 182
  • [7] The Pandemic (H1N1) 2009 Virus Vaccine
    Molyneux, Jacob
    [J]. AMERICAN JOURNAL OF NURSING, 2009, 109 (09) : 19 - 19
  • [8] Effectiveness of H1N1 vaccine against reported Influenza A (H1N1) Southern China, October 2009-February 2010
    Fu, Chuanxi
    [J]. HUMAN VACCINES, 2010, 6 (09): : 767 - 768
  • [9] Monitoring the safety of pandemic H1N1 vaccine
    Huang, Wan-Ting
    Chuang, Jen-Hsiang
    Kuo, Steve Hsu-Sung
    [J]. LANCET, 2010, 375 (9721): : 1164 - 1164
  • [10] Effectiveness of vaccine against influenza A (H1N1) 2009 pdm in preventing household transmission
    Yamada, A.
    Okuno, T.
    Baba, K.
    Okuno, Y.
    Maeda, K.
    Kase, Y.
    Takahashi, K.
    Yasui, Y.
    Okabe, N.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 : E366 - E366